Plain-language summary

This Phase 1 trial is testing Alectinib and Duvelisib for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 7 US locations across multiple states.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)
• May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Alectinib (DRUG): All patients will receive a lead-in cycle (28 days) of alectinib. | Duvelisib (DRUG): After the lead-in cycle of alectinib, in the absence of progressive disease as assessed by PET/CT scan, all patients will then receive two 28-day cycles of alectinib plus duvelisib.

Drugs / treatments

Alectinib, Duvelisib

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details